Anzeige
Mehr »
Montag, 25.05.2026 - Börsentäglich über 12.000 News
Diese 0,13 €-Aktie besitzt 2 der wichtigsten kritischen Metalle der Welt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41G7H | ISIN: US8964386036 | Ticker-Symbol: TRB0
NASDAQ
22.05.26 | 21:50
0,605 US-Dollar
+0,50 % +0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRINITY BIOTECH PLC ADR Chart 1 Jahr
5-Tage-Chart
TRINITY BIOTECH PLC ADR 5-Tage-Chart

Aktuelle News zur TRINITY BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TRINITY BIOTECH Aktie jetzt für 0€ handeln
06.05.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer2
01.05.Trinity Biotech reports FY results6
01.05.Trinity Biotech plc: Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations1.722- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transformation...
► Artikel lesen
30.04.TRINITY BIOTECH PLC - 20-F, Annual and transition report of foreign private issuers2
25.03.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer14
23.03.Trinity Biotech reports clinical study results for prostate test4
23.03.Trinity Biotech plc: Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture Prostate Cancer Test930Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK...
► Artikel lesen
18.03.Trinity Biotech plc: Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome4
12.03.Trinity Biotech plc: Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System1.634Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech...
► Artikel lesen
11.03.Trinity Biotech plc: Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program4
10.03.Trinity Biotech meldet Fortschritte beim CGM+-System und plant zulassungsrelevante Studie für 20263
10.03.Trinity Biotech plc: Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform831- Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics...
► Artikel lesen
10.03.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer-
10.03.Trinity Biotech plc: Trinity Biotech Provides Business and Trading Update944DUBLIN, March 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable...
► Artikel lesen
25.02.Trinity Biotech raises $25M as it looks to advance CGM+ system2
25.02.Trinity Biotech sichert sich Eigenkapitalfinanzierung über 25 Millionen US-Dollar18
25.02.Trinity Biotech enters $25M standby equity purchase agreement1
25.02.TRINITY BIOTECH PLC - F-1, Registration statement for certain foreign private issuers13
25.02.Trinity Biotech plc: Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives492- Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovation...
► Artikel lesen
20.02.Trinity Biotech erhält Delisting-Warnung von der NASDAQ4
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1